Clinical Trial Finder

Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients

Study Purpose

1. Evaluate serum levels of (MCP-1) in PsA with or without cardiovascular affaction . 2. Detect subclinical cardiovascular affaction in patients with PsA for early diagnosis and management .

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

 Yes
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

 Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - PsA patients (age ≥ 18years) who fulfilled the CASPAR classification criteria[15]for psoriatic arthritis.

Exclusion Criteria:

  • - PsA patients with.
1. infection. 2. bone marrow disorders. 3. other autoimmune diseases. 4. diabetes. 5. hypertention . 6. hyperlipidemia. 7. liver diseases. 8. renal diseases.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

 NCT05637905
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

 Assiut University
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

 Eman Abass, doctorMohamed Raouf, doctorEsraa Ahmed, doctor
Principal Investigator Affiliation Assiut UniversityAssiut UniversityAssiut University
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

 Other
Overall Status Not yet recruiting
Countries
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

 Psoriatic Arthritis
Study Website: View Trial Website
Additional Details

Psoriatic arthritis (PSA) is an autoimmune disease arising from the interply between proinflamatory cytokines. [1]and external stimuli in genetically predisposed individuals.[2]

  • - The disease is chronic and affects the peripheral joints and may include axial skeleton with or without extrarticular manifestations.
[3]
  • - Abnormal activation of the innate and adaptive immune systems contributes to chronic disease processes in both psoriasis and PSA .
[4] The skin and the joints exhibit a prominent lymphocytic infiltrate consisting of activated CD4+ and CD8+ T cells as well as an increase in neutrophil infiltration[5]. Patients with PsA have a higher risk of developing a cardiovascular(CV) events than the general population. This could be attributed to the higher prevalence of traditional cardiovascular risk factors and to the disease characteristics such as systemic inflammation. [6] These patients may show asymptomatic cardiomyopathy even in the absence of traditional risk factors [7].Cardiac dysfunction is associated with a poor prognosis, increased mortality, and affact socioecenomic function of patients therefore, the diagnosis of the cardiac dysfunction in the asymptomatic phase of the disease [8] is important for the timely introduction of therapy [9].Monocyte chemotactic protien1(MCP-1) is a member of chemotactic chemokines(CC) which are secreted by immune effector cells and dysfunctional endothelium [10].
  • - The pivotal function of MCP-1 is to attract monocyte in the arterial wall through increased expression of adhesion molecules on their surface that interacts with endothelium[11].
  • - MCP-1 induce maturation of monocyte in the arterial wall ,which then become specialized macrophage in early atheroma and produce tissue factors supporting coagulation and proinflammatory cytokines such as IL-1 and IL-6.
It affects the functions of the surrounding immune effector cells in locally thickened intima.[12]
  • - During active disease in psoriatic skin lesions and synovial tissue, activated monocytes represent the major source of proinflammatory mediators, including the chemokine MCP-1 [13].
MCP-1 is thought to be involved in the pathogenesis of oedema and bone erosion in patients with PsA [14].

Arms & Interventions

Arms

: psoriatic arthritis patients group

: health control group

Interventions

Contact Information

This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:

Amira Anas, Master

amiraanas60@gmail.com

01066633924

For additional contact information, you can also visit the trial on clinicaltrials.gov.

Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.